Revenue
2022
2023
2024
2025
Thalia Therapeutics plc (THAT)
Price£0.0055Cached quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £7,264 | £7,282 | £1,953 | £0 |
| Research & development | £214,120 | £390,387 | £619,392 | £577,525 |
| Operating expenses | £1.2M | £1.2M | £1.3M | £1.2M |
| Operating income | −£1.2M | −£1.2M | −£1.3M | −£1.2M |
| Operating margin | −16,882.52% | −15,928.19% | −68,377.83% | — |
| EBITDA | −£1.2M | −£1.2M | −£1.3M | −£1.2M |
| EBITDA margin | −16,882.52% | −15,928.19% | −68,377.83% | — |
| Net income | −£1.2M | −£1.1M | −£1.3M | −£1.0M |
| Net profit margin | −16,588.77% | −14,537.52% | −64,993.91% | — |
| Basic EPSper basic share | -£0.00 | -£0.00 | -£0.01 | -£0.01 |
| Diluted EPSper diluted share | -£0.00 | -£0.00 | -£0.01 | -£0.01 |